Feraccru is a unique, non-salt, formulation oral iron: strong efficacy with “placebo-like” tolerability Potential to change iron deficiency anaemia (IDA) therapeutic algorithm Feraccru to become the preferred option for patients not...

Shield Therapeutics PLC

Shield Therapeutics PLC

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company’s clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

Market: LSE
52-week High/Low:
Sector: Pharma & Biotech
Market Cap: 95.21M

Popular Content

Tag Content

Shield Therapeutics PLC Timeline